磷酸二酯酶抑制剂在女性性功能障碍治疗中的应用：范围综述。
The use of phosphodiesterase inhibitors in the treatment of female sexual dysfunction: scoping review.
机构信息
USF São Vicente Porto Portugal Family Medicine, USF São Vicente, Porto, Portugal.
USF Renascer Porto Portugal Family Medicine, USF Renascer, Porto, Portugal.
出版信息
Rev Bras Ginecol Obstet. 2024 Jul 26;46. doi: 10.61622/rbgo/2024rbgo49. eCollection 2024.
OBJECTIVE
The purpose of this study was to analyze the available evidence regarding the efficacy of iPDE5 in the treatment of female sexual dysfunction (FSD).
METHODS
A comprehensive literature search was conducted in March 2023 through the main scientific databases.
RESULTS
A total of 53 articles were identified, out of which, 6 met the predefined inclusion criteria. All of these were randomized controlled trials. Among the included studies, 4 demonstrated the effectiveness of sildenafil in improving sexual response and addressing FSD, while 2 studies failed to establish its efficacy in this context.
CONCLUSION
Overall, the efficacy of sildenafil in the treatment of FSD remains controversial and inconclusive based on the available evidence. Further research is necessary to clarify the therapeutic potential of iPDE5 in addressing FSD and to better understand the factors that influence treatment outcomes.
目的
本研究旨在分析 iPDE5 在治疗女性性功能障碍（FSD）方面的疗效的现有证据。
方法
2023 年 3 月，通过主要科学数据库进行了全面的文献检索。
结果
共确定了 53 篇文章，其中 6 篇符合预先设定的纳入标准。这些都是随机对照试验。在纳入的研究中，4 项研究表明西地那非在改善性反应和治疗 FSD 方面有效，而 2 项研究未能在这方面证实其疗效。
结论
根据现有证据，西地那非治疗 FSD 的疗效仍存在争议和不确定性。有必要进行进一步的研究，以阐明 iPDE5 在治疗 FSD 方面的治疗潜力，并更好地了解影响治疗结果的因素。
Zotero 插件